Gpr35 deficiency was found to exacerbate motor dysfunction, dopaminergic neurodegeneration, and neuroinflammation in PD models, while activation of Gpr35 by the agonist KYNA demonstrated substantial neuroprotective and anti-inflammatory effects. This evidence concerns the gene GPR35 and Parkinson disease.